This week, three publications in the healthcare policy and regulatory affairs industries referenced MGA’s recent report on the potential savings from accelerating US approval of complex generics.
Matrix Global Advisors (MGA) today released a new report, “Potential Savings from Accelerating US Approval of Complex Generics,” by MGA founder and CEO Alex Brill.
“The report finds that extending patents on just those five drugs [Prilosec, TriCor, Suboxone, Doryx, and Namenda] will result in a cost to the U.S. health care system of $4.7 billion annually—money that in theory could have been saved if the drugs had been available in a generic form.”
“An anti-competitive tactic used by brand-name drugmakers called product hopping costs the U.S. healthcare system at least $4.7 billion annually, according to a study from Matrix Global Advisors.”
Report details five instances of product hopping that collectively cost $4.7 billion annually.
This report examines the BLOCKING Act and why it is a misguided attempt at promoting generic drug competition.